Human immunodeficiency virus-associated progressive multifocal leucoencephalopathy: epidemiology and predictive factors for prolonged survival

Authors: Drake, A. K.1; Loy, C. T.2; Brew, B. J.; Chen, T. C. C.3; Petoumenos, K.4; Li, P. C. K.5; Wright, E. J.

Source: European Journal of Neurology, Volume 14, Number 4, April 2007 , pp. 418-423(6)

Publisher: Blackwell Publishing

Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content

Abstract:

We performed a retrospective review of cases of human immunodeficiency virus-associated progressive multifocal leucoencephalopathy in four hospitals (three in Australia and one in Hong Kong) between 1987 and 2003 in order to describe the local experience with this disease and to evaluate parameters impacting upon survival. Eighty-seven cases were identified and demographic details, baseline parameters and treatment methods and response were described. Survival was substantially increased in the post-highly active antiretroviral therapy (HAART) era with a median survival increase from 14 to 64 weeks. On multivariate analysis, variables associated with prolonged survival included a CD4 count of >100 cells/μl at diagnosis and the use of HAART post-diagnosis, with no significant additional advantage from the use of neuroactive antiretrovirals.

Keywords: antiretroviral therapy; human immunodeficiency virus; progressive multifocal leucoencephalopathy; survival

Document Type: Research article

DOI: 10.1111/j.1468-1331.2007.01686.x

Affiliations: 1: Infectious Diseases Unit, The Alfred Hospital, Melbourne, Vic., Australia 2: Departments of Neurology and HIV Medicine, St Vincent's Hospital, Sydney, NSW, Australia 3: University of New South Wales, Sydney, NSW, Australia 4: National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Sydney, NSW, Australia 5: Department of Medicine, Queen Elizabeth Hospital, Hong Kong, China; and

The full text electronic article is available for purchase. You will be able to download the full text electronic article after payment.

$50.39 plus tax      Refund Policy

 

OR

Back to top

Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content
Share this item with others: These icons link to social bookmarking sites where readers can share and discover new web pages.
Page Help Click here for Page Help
Shopping cart
Tools
Sign in






Need to register?
Sign up here
Text size: A | A | A | A